RIPK2-IN-7

RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM) . RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα) . RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) [1].

Product Specifications

CAS Number

[2789711-40-4]

UNSPSC

12352005

Target

NOD-like Receptor (NLR) ; RIP kinase; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

NC1=C2C(C3=C(C=C(C=C3)C)F)=CN([C@H]4CC[C@H](CC4)N)C2=NC=N1

Molecular Formula

C19H22FN5

Molecular Weight

339.41

References & Citations

[1]Yuan X, et al. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs) . J Med Chem. 2022 Jul 14;65 (13) :9312-9327.